» Articles » PMID: 39076974

Lymphocyte Homing and Recirculation with Tumor Tertiary Lymphoid Structure Formation: Predictions for Successful Cancer Immunotherapy

Overview
Journal Front Immunol
Date 2024 Jul 30
PMID 39076974
Authors
Affiliations
Soon will be listed here.
Abstract

The capacity of lymphocytes continuously home to lymphoid structures is remarkable for cancer immunosurveillance and immunotherapy. Lymphocyte homing and recirculation within the tumor microenvironment (TME) are now understood to be adaptive processes that are regulated by specialized cytokines and adhesion molecule signaling cascades. Restricted lymphocyte infiltration and recirculation have emerged as key mechanisms contributing to poor responses in cancer immunotherapies like chimeric antigen receptor (CAR)-T cell therapy and immune checkpoint blockades (ICBs). Uncovering the kinetics of lymphocytes in tumor infiltration and circulation is crucial for improving immunotherapies. In this review, we discuss the current insights into the adhesive and migrative molecules involved in lymphocyte homing and transmigration. The potential mechanisms within the TME that restrain lymphocyte infiltration are also summarized. Advanced on these, we outline the determinates for tertiary lymphoid structures (TLSs) formation within tumors, placing high expectations on the prognostic values of TLSs as therapeutic targets in malignancies.

Citing Articles

HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.

Baek B, Park H, Choi J, Lee E, Seong S Pharmaceutics. 2025; 17(1).

PMID: 39861713 PMC: 11769570. DOI: 10.3390/pharmaceutics17010065.


The potential of cellular homing behavior in tumor immunotherapy: from basic discoveries to clinical applications of immune, mesenchymal stem, and cancer cell homing.

Li D, Yang Y, Zheng G, Meng L, Shang L, Ren J Front Immunol. 2024; 15:1495978.

PMID: 39726590 PMC: 11669694. DOI: 10.3389/fimmu.2024.1495978.


Subverting to Prevent : Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion.

Mastrogiovanni M, Donnadieu E, Pathak R, Di Bartolo V Biology (Basel). 2024; 13(11).

PMID: 39596815 PMC: 11591779. DOI: 10.3390/biology13110860.

References
1.
Bekkhus T, Martikainen T, Olofsson A, Boger M, Bacovia D, Warnberg F . Remodeling of the Lymph Node High Endothelial Venules Reflects Tumor Invasiveness in Breast Cancer and is Associated with Dysregulation of Perivascular Stromal Cells. Cancers (Basel). 2021; 13(2). PMC: 7827313. DOI: 10.3390/cancers13020211. View

2.
Hickman A, Koetsier J, Kurtanich T, Nielsen M, Winn G, Wang Y . LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022; 132(13). PMC: 9246385. DOI: 10.1172/JCI154152. View

3.
Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E . Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022; 40(3):318-334.e9. DOI: 10.1016/j.ccell.2022.01.002. View

4.
Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H . IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021; 14(1):118. PMC: 8323212. DOI: 10.1186/s13045-021-01128-9. View

5.
Bui T, Wiesolek H, Sumagin R . ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020; 108(3):787-799. PMC: 7977775. DOI: 10.1002/JLB.2MR0220-549R. View